**Generation of false positive SARS-CoV-2 antigen results with testing conditions outside manufacturer**

**recommendations: A scientific approach to pandemic misinformation**

Glenn Patriquin[1,2], Ross J. Davidson[1-4], Todd F. Hatchette[1-4], Breanne M. Head[5], Edgard Mejia[5], Michael G.

Becker[5], Adrienne Meyers[5], Paul Sandstrom[5], Jacob Hatchette[6], Ava Block[6], Nicole Smith[6], John Ross[6],

Jason J. LeBlanc[1-4*]

[1]Division of Microbiology, Department of Pathology and Laboratory Medicine, Nova Scotia Health (NSH),

Halifax, Nova Scotia, Canada.

[2]Department of Pathology, Dalhousie University, Halifax, Nova Scotia, Canada.

[3]Department of Medicine (Infectious Diseases), Dalhousie University, Halifax, Nova Scotia, Canada.

[4]Department of Microbiology and Immunology, Dalhousie University, Halifax, Nova Scotia, Canada.

[5]National Microbiology Laboratory (NML), Public Health Agency of Canada (PHAC), Winnipeg, Manitoba,

Canada.

[6]Praxes Medical Group, Halifax, Nova Scotia, Canada.

**Key Words:** COVID-19, SARS-CoV-2, antigen, false positive, Panbio

**Abstract word count:** 250

**Body word count:** 2989

**\*Corresponding author:**       Jason J. LeBlanc, PhD, FCCM, D(ABMM)

18                                      Division of Microbiology, Department of Pathology and Laboratory

19                                      Medicine, Nova Scotia Health (NSH),

20                                      Room 404B, MacKenzie Building

21                                      5788 University Avenue, Halifax, Nova Scotia, B3H 1V8

22                                      Tel.: +1 902 473 7698; Fax: +1 902 473 7971

23                                      Email: jason.leblanc@nshealth.ca

**Abstract**

**Objectives.** Antigen-based rapid diagnostics tests (Ag-RDTs) are useful tools for SARS-CoV-2 detection.

However, misleading demonstrations of the Abbott Panbio COVID-19 Ag-RDT on social media claimed

that SARS-CoV-2 antigen could be detected in municipal water and food products. To offer a scientific

rebuttal to pandemic misinformation and disinformation, this study explored the impact of using the

Panbio SARS-CoV-2 assay with conditions falling outside of manufacturer recommendations.

**Methods.** Using Panbio, various water and food products, laboratory buffers, and SARS-CoV-2-negative

clinical specimens were tested, with and without manufacturer buffer. Additional experiments were

conducted to assess the role of each Panbio buffer component (tricine, NaCl, pH, and tween-20), as well

as the impact of temperatures (4°C, 20°C , and 45°C) and humidity (90%) on assay performance.

**Results.** Direct sample testing (without the kit buffer), resulted in false positive signals resembling those

obtained with SARS-CoV-2-positive controls tested under proper conditions. The likely explanation of

these artifacts is non-specific interactions between the SARS-CoV-2-specific conjugated and capture

antibodies, as proteinase K treatment abrogated this phenomenon, and thermal shift assays showed pH-

induced conformational changes under conditions promoting artifact formation. Omitting, altering, and

reverse engineering the kit buffer all supported the importance of maintaining buffering capacity, ionic

strength, and pH for accurate kit function. Interestingly, the Panbio assay could tolerate some extremes

of temperature and humidity outside of manufacturer claims.

**Conclusions.** Our data support strict adherence to manufacturer instructions to avoid false positive

SARS-CoV-2 Ag-RDT reactions, otherwise resulting in anxiety, overuse of public health resources, and

dissemination of misinformation.

## Introduction

High demand for diagnostic testing during the COVID-19 pandemic led to the development of various

technologies for SARS-CoV-2 detection.[1] Nucleic acid amplification tests (NAATs), like real-time RT-

PCR, are considered the reference methods [2-4], but antigen-based rapid diagnostic tests (Ag-RDTs)

have been widely used due to their ease-of use, rapid results, and ability to be performed outside of a

laboratory setting.[1] Many Ag-RDTs have been licensed as point-of-care (POC) devices for SARS-CoV-2

detection [5,6], but their performance can vary between methods, testing frequency, and settings in

which they are used.[7-13] Ag-RDTs are well recognized to be less sensitive and specific than commercial

NAATs, and false positive results from Ag-RDTs are known to occur, particularly in settings of low disease

prevalence.[14,15]

Recently, misleading demonstrations of a SARS-CoV-2 Ag-RDT (i.e. Panbio) on social media platforms

have claimed that SARS-CoV-2 antigen can readily be detected in municipal water and commercial food

and beverages; however, direct testing of samples onto Ag-RDTs devices is not recommended by the

manufacturer. With misinformation and disinformation often perpetuated on social media,

unsubstantiated claims can undermine confidence in SARS-CoV-2 diagnostic testing and erode trust in

public health efforts. As such, it is important to use science-based approaches to demonstrate that non-

specific reactivity can occur when testing is performed under inappropriate conditions, and that SARS-

CoV-2 is not truly present in food or potable water samples. This study evaluated conditions that fell

outside of those recommended by the manufacturer, which had the potential to generate aberrant Ag-

RDT reactions, including unregulated buffering capacity or ionic strength, and extremes of temperature,

humidity, and pH.

## Materials and methods

*Samples types*

Ag-RDT samples included food products (Table S1), water, laboratory buffers, specimen transport media,

and 30 each of four different clinical specimens types: 1) nasopharyngeal (NP) swabs in universal

transport media (UTM); 2) oropharyngeal and bilateral nares (OP/N) swabs in phosphate buffered saline

(PBS) [16,17]; 3) bronchoalveolar lavages (BAL); and 4) saline gargles (Table 1).[18,19]

*Antigen and molecular testing*

SARS-CoV-2 nucleocapsid antigen detection was performed using the Abbott Panbio COVID-19 Rapid

Antigen Test and the BD Veritor System for Rapid Detection of SARS-CoV-2. Each kit's nasal swabs were

dipped into the test samples, placed in the appropriate kit buffers, and 3 or 5 drops were used to

inoculate the sample wells of the Veritor and Panbio cassettes, respectively, as per the manufacturer

recommendations. Each sample was also tested without manufacturer buffer (i.e. direct sample testing),

mirroring the procedure and volume recommended for buffer. Results were visualized by the unaided

eye after 15 minutes, and Veritor readouts also included automated detection using a BD Veritor Plus

instrument. Real-time RT-PCR testing was performed for all specimens except food products using the

Roche Diagnostics cobas SARS-CoV-2 Test on the cobas 6800 instrument.

*Assessing Panbio buffer components*

The exact composition of Panbio buffer is proprietary, yet according to the product insert, it consists of

tricine, sodium chloride (NaCl), tween-20, proclin 300, and sodium azide (<0.1%). To assess the role of

these components, the buffer was reverse engineered. PCR-grade water (Invitrogen) was chosen as a

representative matrix to generate false positive Panbio results (Table 1). Solutions of tricine (1 mM to

1M), from pH 3 to 12 were prepared (Figure 1), with or without 1% tween-20. The contribution of ionic

strength was assessed using NaCl (1 mM to 1M) in 100 mM tricine solutions pH 3 to 12 (Figure 2).

*Effect of temperature and humidity on Ag-RDT performance*

Dilutions of gamma-irradiated SARS-CoV-2 were assessed at pre-treatment and operational

temperatures within (20°C), below (4°C), or above [45°C, 90% relative humidity (RH)] the recommended

test conditions (Document S1 and Table S2). Additional experiments evaluated freezing Panbio test

components at -20°C, or long-term incubation (16h) at high humidity and temperature (Document S1).

To assess the limit of tolerance to water-induced artifacts, Panbio buffer was serially diluted and tested

at 4°C, 20°C, and 37°C (Figure 3).

*Investigation of environmental conditions on PanBio performance*

According to manufacturer specifications, PanBio kits should be stored between 2 to 30 °C, and all kit

components brought to room temperature (15 to 30 °C) for 30 minutes prior to use. To assess the

impact of storage temperature, sealed PanBio test devices were incubated for one hour at 4°C, 20°C or

45°C (with 90% relative humidity using a Binder Constant Climate Chamber model KBF 115). Test devices

were removed from their packaging, and incubations were repeated under the same conditions. Testing

was performed using 20 µL of gamma-irradiated SARS-CoV-2 into 280 µL of PanBio buffer. Viral stocks

[at $1.2 \times 10^6$ plaque forming units (PFU)/mL] were diluted in PBS (pH = 7.4) to concentrations spanning

$1.2 \times 10^5$ to $1.1 \times 10^3$ PFU/mL (Supplemental Table S2). PanBio buffer and PBS were used as negative

controls. Freeze-thaw effects were investigated by incubation of test components at -20°C for 16 hours

before thawing and testing. Long-term exposure to high temperature and humidity was investigated by

removing test components from packaging and subjecting them to 16 hours at 45°C (with 90% relative

humidity).

*Investigations into possible causes of false positive results*

Using "conjugate pad transplantation" (Figure S1), the proprietary gold conjugated-antibodies of the

Panbio device (i.e. the SARS-CoV-specific human IgG and the chicken IgY used for the control) were

accessed from disassembled Panbio cassettes. Each conjugate pad was resuspended with 100 µl of

Panbio buffer, PCR-grade water, or tricine solutions, and the suspensions were subjected to various

treatments. Proteinase K (PK) (Qiagen GmbH., Hilden, Germany) was used at 100 µg/reaction for one

hour at 56°C, followed by enzyme inactivation at 70°C for 10 minutes. Untreated and heat treatment

controls were included as controls (Figure S2). The remaining conjugate-free pads are washed three

times with 1 ml of water or buffer, dried using a Whatman #1 filter, and re-introduced into the Panbio

cassettes. For testing, 25 µl of each water- or buffer-derived conjugated-antibody suspension was added

onto the conjugate pads of reassembled cassettes, followed by addition of 5 drops into the sample well

of either positive or negative controls processed in water or the kit buffer.

In a second set of experiments (Figure S1, dashed lines), the control chicken IgG was removed from the

SARS-CoV-2-specific IgG by pre-treatment of the conjugate suspensions with a fragment of the

nitrocellulose membrane from the Panbio test device containing the immobilized mouse monoclonal

anti-chicken IgY. Fragments were excised at approximately 3 mm on each side of the control line

indicated on the Panbio cassette. For each 100 µl of conjugate suspension, one fragment was added,

followed by a 15 min incubation at room temperature. Then, SARS-CoV-2-specific conjugated antibody

were removed and subjected to thermal shift assays [20-22] to explore possible pH-induced

conformational changes (Figure S3).

*Conjugated SARS-CoV-2 IgG thermal shift assays*

Differential scanning fluorometry (DSF), also known as thermal shift assays, relies on monitoring

temperature-dependent unfolding of a protein, in presence of a fluorescent dye that is quenched in

water but fluoresces when bound to hydrophobic residues.[20-22]  As a native protein is unfolded with

heat, different hydrophobic residues are exposed, and the melting temperature (Tm) can be calculated

for various test conditions. In this study, 25 µl reaction containing 10× SYPRO Orange (Invitrogen,

Eugene, Oregon, USA) was added to the gold-conjugated human IgG specific to SARS-CoV-2

resuspended in Panbio buffer or 100 mM of tricine at pH values spanning 3 to 12, with or without 1%

tween-20. Melting curve analysis was performed by increasing the temperature from 25°C to 99.9°C at a

ramp rate of 1% with continuous fluorescence at 610 nm using an Applied Biosystems 7500 Fast

instrument. Tm values were calculated by manufacturer software (Figure S3).

**Results**

*False positives in food, water, buffers, media, and clinical specimens*

With the exception of soft drinks and some milk products which produced negative or weak false

positive reactions, most of the food products that were tested directly onto the Panbio cassette

produced a strong positive SARS-CoV-2 signals that resembled those obtained with the kit positive

control (Table S1). Direct testing of highly acidic samples caused invalid results for both Panbio and

Veritor. All other products were Veritor-negative. When nasal swabs were used to sample the various

products and processing occurred with manufacturer buffer, no false positives or invalid results were

observed.

Multiple water samples were evaluated with tested pH values between 4.00 and 9.33, and differences in

supplier-described purification methods, and mineral and electrolyte composition (Table 1). Direct

testing onto Panbio test devices showed strong false positive SARS-CoV-2 signals, while samples diluted

in Panbio buffer did not produce any artifacts. Notably, water samples near the pH of the Panbio buffer

(pH 8.78) also displayed strong false positive signals, suggesting the mechanism behind artifact

formation is not, or not solely, pH-dependent. To investigate the possible roles of buffering capacity and

ionic strength, commonly used laboratory buffers and buffer-containing viral transport media spanning

various pH values (5.62 to 8.78) were tested (Table 1). With the exception of Tris-EDTA (TE), all other

buffers and media generated weakly positive or negative results (Table 1). All water samples, buffers,

and media were RT-PCR and Veritor-negative, suggesting absence of viral RNA and nucleocapsid antigen,

respectively (Table 1).

Given that weak false positive were results observed with UTM, PBS, and saline, direct testing was

performed on clinical specimens containing these media and buffers. With direct testing onto Panbio

cassettes, false positive results were seen in 93.3% of NP swabs in UTM, 86.7% of OP/N swabs in PBS,

90.0% of BALs, and 90.0% of the saline gargles (Table 1). All specimens were negative when Panbio

buffer was used, which was consistent with the Veritor and RT-PCR results.

*Role of Panbio buffer components*

Tricine solutions at 1M prevented artifact formation at pH values ≥7, whereas strong false positive SARS-

CoV-2 results were seen at pH ≤ 5 (Figure 1). At 100 mM tricine, buffering capacity was narrowed, and

non-specific SARS-CoV-2 bands were seen at pH ≤ 8. With the exception of invalid results obtained at pH

3 and 12, false positive results at either 1 or 10 mM of tricine when pH ranged between 4 and 11.

Tween-20 (1%) was added to all tricine solutions, but had no impact on results (data not shown). Ionic

strength was assessed with various NaCl concentrations in 100 mM tricine solutions, pH 3 to 12 (Figure

2). High concentration of NaCl (1M) prevented artifact formation, 100 mM reduced it, and lower

concentrations (1 and 10 mM) mirrored NaCl-free conditions (Figure 1 and 2). Antimicrobial agents in

the Panbio buffer (i.e. proclin 300 and sodium azide) were not investigated due to their unlikely

contribution to artifact generation.

*Investigations into the mechanism of artifact generation*

Following conjugate pad transplantation, positive and negative control swabs displayed expected results

after inoculation onto re-assembled Panbio cassettes in which resuspended conjugated antibodies were

re-introduced. Water-resuspended conjugated antibody generated a strong false positive target signal,

which was eliminated following PK treatment (Figure S2). Removal of the gold-conjugated IgY antibody

from the conjugate suspensions did not impair Panbio test performance, and the strong false positive

SARS-CoV-2 signal from water remained (Figure S2). These findings suggest that the gold-conjugated

human anti-SARS-CoV-2 IgG is responsible for the non-specific interactions with the immobilized anti-

SARS-CoV-2 capture antibody on the test device nitrocellulose membrane. Thermal shift assays in 100

mM tricine solutions were used to compare structural differences of the anti-SARS-CoV-2 IgG at

different pH (Figure S3), and Tm values were significantly different in tricine solutions between pH 5 to 7

(at 68.4 ± 2.6, 71.4 ± 1.2, 72.5 ± 1.0, respectively) compared to pH 8 to 10 (at 75.6 ± 1.0, 76.8 ± 1.1 and

77.6 ± 1.4, respectively) (Figure S3). Tm values at pH 4 and 11 were inconsistent, while no Tm values

could be established at pH 3 and 12.

*Impact of heat and humidity on Panbio kit function*

In all test conditions evaluated (Table S1), no deleterious effects on test sensitivity or specificity were

observed concerning temperature or humidity. In a complimentary series of experiments, Panbio buffer

was able to tolerate dilutions with water (without generating artifacts) up to a ratio of 1:10, regardless

of operating temperature (Figure 3).

**Discussion**

False positive and negative results occur with any diagnostic test, but are increasingly likely when

manufacturer recommendations are not followed.[1,14,15] Using the Panbio SARS-CoV-2 Ag-RDT, this

study demonstrated test conditions outside manufacturer recommendations that can cause false

positive results. In absence of manufacturer buffer, a variety of food, water, laboratory buffer, specimen

transport media, and clinical specimens showed false positive reactions. Uncontrolled conditions of pH,

buffering capacity, and ionic strength, all favored artifact generation, whereas temperature and

humidity were not contributory under the tested parameters.

The principal components of the Panbio buffer, tricine and NaCl, were shown to help maintain buffering

capacity, ionic strength, and pH compatible with the proper function of the assay. Panbio buffer diluted

in water at ratios greater than 1:10 resulted in artifact formation. Similarly, when buffering capacity was

poor or lost when using low tricine concentrations (1 or 10 mM), strong false positive signals were seen

across a broad range of pH values. In contrast, high tricine concentrations (100 mM or 1M) prevented

artifact formation at pH 9 and above, which is consistent with the measured pH of Panbio buffer at 8.78.

Similarly, regulated ionic strength also played an important role, as high NaCl concentrations (100 mM

or 1M) reduced or prevented false positive results. Of note, strong artifacts were generated with most

food and water samples, due to their poor buffering capacity and ionic strength, whereas only weak

positive or negative results seen with buffers, media, and clinical specimens. These data are consistent

with others [23] who recognized the importance of Ag-RDT kit buffers.

Other possible explanations for false positive Ag-RDT results include cross-reactions [24], interfering

substances [25,26], and improper operating or storage conditions for temperature or humidity.[27].

Cross-reacting or interfering substances common to all samples tested in the study is unlikely.

Temperature extremes have been shown to induce conformational changes in antibodies leading to

non-specific binding [28]; however, in this study, Panbio was unaffected by temperature and humidity.

As mentioned above, the most likely cause of Panbio false positive results was aberrant protein-protein

interactions faced with improper buffer conditions, ionic strength, or pH.

In a previous study, 20 of 27 of the malaria Ag-RDTs brands evaluated showed false positive reactions

when the manufacturer buffer was replaced with saline, tap water, or distilled water.[23] Distilled water

alone generated false positive reactions [23], similar to what was observed in this study with Panbio.

Possible explanations for their findings included inefficient resuspension of blocking agents, altered

capillary flow rates and decreased flushing of contaminating substances, and finally, non-specific

interactions between the conjugated and capture antibodies faced with uncontrolled buffering and ionic

strength conditions.[23] Tricine is a zwitterionic amino acid with a pKa of 8.26, and in the Panbio buffer,

would be negatively charged at the measured pH of 8.78. Therefore, under recommended testing

conditions, tricine may mask positively charged residues on the SARS-CoV-2-specific conjugated and

capture antibodies, while uncontrolled buffer conditions would favor aberrant electrostatic or

hydrophobic interactions between the two antibodies, resulting in false positive results. Supporting this

theory, PK treatment eliminated the false positive Panbio results generated by water, and the

propensity to generate this artifact varied with buffering capacity, pH, and ionic strength. Removal of

the gold-conjugated chicken IgY (used for control band detection) did not alter formation of the SARS-

CoV-2 target artifact formation, suggesting the SARS-CoV-2-specific conjugated IgG alone is responsible

for non-specific binding and to the SARS-CoV-2-specific capture antibody and artifact formation. Finally,

thermal shift assays were performed on the conjugated anti-SARS-CoV-2 IgG, and pH-dependent

conformation changes were observed under conditions causing false positive results.

False positive reactions with the Panbio Ag-RDT have the potential to cause a significant impact to Public

Health. To date, over 200 million Panbio Ag-RDT tests have been distributed to over 120 countries

worldwide, for use in healthcare settings, businesses, or home self-testing. In low prevalence

populations, positive Ag-RDTs are typically confirmed by clinical laboratories with NAATs, thereby

limiting the overall public health impact of the possible artifacts described in this study.[2-4] However, in

programs where home self-testing kits are deployed, it is important to educate users on the importance

of strict adherence to manufacturer instructions. Such education could prevent overuse of public health

and laboratory resources required to investigate false positive reactions, and may alleviate anxieties for

the impacted individuals.[17,19,29,30] Another area for consideration is outdoor testing strategies (e.g.

drive-thru testing), where the Panbio kit supplies may be exposed to precipitation and fluctuations in

temperature and humidity.[30] To reduce potential aberrant results from humidity, each Panbio

cassette is packaged with a desiccant; however, hypothetically, once opened, the accumulation of

moisture in humid environments could cause false positive results. Prolonged exposure to elevated

temperatures has been shown to affect the sensitivity of SARS-CoV-2 detection by Ag-RDTs, whereas

low temperatures impaired specificity.[25] This could potentially impact Ag-RDT programs in countries

where extreme environmental conditions are relevant, particularly in those where access to NAAT-

based confirmatory testing is limited. While temperature and humidity did not alter the Panbio

performance in this study, rain water was shown to cause false positive reactions if processed without

buffer. An alternative explanation for the false positives observed at low temperatures by Haage et al

[25] is their use of non-validated specimen types (i.e. NP swabs in PBS). In this study, PBS alone caused

false positive results in absence of buffer, as did most of the saline-based clinical specimens. While PBS

could be a contributing factor in the generation of false positive results, the quantity of PBS material (i.e.

20 µl) used by Haage et al.[25] should not have overwhelmed the kit buffer, as this study demonstrated

tolerance to dilution up to a ratio of 1:10.

Overall, this manuscript provides rigorous scientific evidence that erroneous false positive SARS-CoV-2

results can occur with improper test conditions, resulting in non-specific interaction between the SARS-

CoV-2-specific conjugated and capture antibodies. As such, SARS-CoV-2 Ag-RDTs should not deviate

from manufacturer instructions.

**Acknowledgement**

The authors would like to thank the Special Pathogens Program of the National Microbiology Laboratory

(NML) (Winnipeg, MB) for the gamma-irradiated SARS-CoV-2 virus used in this study. We would also like

to recognize the ongoing efforts of the all the NML and NSH staff for their dedication and exceptional

services throughout the pandemic, including the help with RT-PCR testing during this evaluation. The

authors would also like to thank all the volunteers and healthcare professionals who dedicate their time

at popup clinics that use Ag-RDTs. You are all instrumental for our pandemic responses, and safety in

our communities.

**Author contributions**

**Transparency declaration**

The authors declare that they have no conflicts of interest.  This work received no private or public

funding, with the exception of the Panbio kits that were provided in-kind from the Public Health Agency

of Canada (PHAC).

**Ethics**

This evaluation was deemed exempt from Nova Scotia Health Research Ethics Board approval, as the

activities described in this manuscript were conducted in fulfillment of ongoing verification of SARS-CoV-

2 diagnostic assays used in Nova Scotia, and are therefore considered a quality assurance initiative.

Clinical specimens tested were obtained from anonymized residual samples collected for routine

diagnostic testing for SARS-CoV-2 from consenting participants, and all data related to clinical specimens

were provided anonymized, de-identified, and were used solely with the intent to evaluate the potential

for false positives in these clinical specimen types for rapid antigen testing programs used in Nova

Scotia.

**References**

1. Safiabadi Tali SH, LeBlanc JJ, Sadiq Z, Oyewunmi OD, Camargo C, Nikpour B, Armanfard N, Sagan SM,

Jahanshahi-Anbuhi S. 2021. Tools and techniques for severe acute respiratory syndrome coronavirus

2 (SARS-CoV-2)/COVID-19 detection. Clin Microbiol Rev. 34(3):e00228-20. doi: 10.1128/CMR.00228-

20. PMID: 33980687.

2. Public Health Agency of Canada (PHAC). 2020. Interim guidance on the use of rapid antigen

detection tests for the identification of SARS-CoV-2 infection. https://www.canada.ca/en/public-

health/services/diseases/2019-novel-coronavirus-infection/guidance-documents/use-rapid-antigen-

detection-tests.html  (accessed June 21, 2021).

3. World Health Organization (WHO). 2020. Antigen-detection in the diagnosis of SARS-CoV-2 infection

using rapid immunoassays. Interim guidance. https://www.who.int/publications/i/item/antigen-

detection-in-the-diagnosis-of-sars-cov-2infection-using-rapid-immunoassays (accessed June 21,

2021)

4. Centers for Disease Control and Prevention (CDC). 2020. Interim guidance for antigen testing for

SARS-CoV-2. https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antigen-tests-

guidelines.html (accessed June 21, 2021).

5. US Food and Drug Administration. 2020. In vitro diagnostics EUAs. https://www.fda.gov/medical-

devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/vitro-

diagnostics-euas#individual-molecular (accessed June 21, 2021).

6.   Health Canada. 2020. Authorized medical devices for uses related to COVID-19: List of authorized

testing devices. https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-

industry/medical-devices/authorized/list.html (accessed June 21, 2021).

7.   Patriquin G, LeBlanc JJ. SARS-CoV-2 sensitivity limbo - How low can we go? Int J Infect Dis. 2021

Feb;103:23-24. doi: 10.1016/j.ijid.2020.11.138. Epub 2020 Nov 17. PMID: 33212261; PMCID:

PMC7669480.

8.   Merino P, Guinea J, Muñoz-Gallego I, González-Donapetry P, Galán JC, Antona N, Cilla G, Hernáez-

Crespo S, Díaz-de Tuesta JL, Gual-de Torrella A, González-Romo F, Escribano P, Sánchez-Castellano

MÁ, Sota-Busselo M, Delgado-Iribarren A, García J, Cantón R, Muñoz P, Folgueira MD, Cuenca-

Estrella M, Oteo-Iglesias J; Spanish Panbio™ COVID-19 validation group. 2021. Multicenter

evaluation of the Panbio COVID-19 rapid antigen-detection test for the diagnosis of SARS-CoV-2

infection. Clin Microbiol Infect. 27(5):758-61. doi: 10.1016/j.cmi.2021.02.001. Epub ahead of print.

PMID: 33601009; PMCID: PMC7884234.

9.   Scheiblauer H, Filomena A, Nitsche A, Puyskens A, Corman VM, Drosten C,  Zwirglmaier K,  Lange C,

Emmerich P,  Müller M,  Knauer O,  Nübling CM. 2021. Comparative sensitivity evaluation for 122

CE-marked SARS-CoV-2 antigen rapid tests. medRxiv 2021.05.11.21257016; doi:

https://doi.org/10.1101/2021.05.11.21257016

10. Gremmels H, Winkel BMF, Schuurman R, Rosingh A, Rigter NAM, Rodriguez O, Ubijaan J, Wensing

AMJ, Bonten MJM, Hofstra LM. 2021. Real-life validation of the Panbio COVID-19 antigen rapid test

(Abbott) in community-dwelling subjects with symptoms of potential SARS-CoV-2 infection.

EClinicalMedicine 31:100677. https://doi.org/10.1016/j.eclinm.2020.100677.

11. Linares M, Pérez-Tanoira R, Carrero A, Romanyk J, Pérez-García F, Gómez-Herruz P, Arroyo T,

Cuadros J. 2020. Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7

days after the onset of symptoms. J Clin Virol. 133:104659. doi: 10.1016/j.jcv.2020.104659. Epub

2020 Oct 16. PMID: 33160179; PMCID: PMC7561603.

12. Albert E, Torres I, Bueno F, Huntley D, Molla E, Fernández-Fuentes MÁ, Martínez M, Poujois S,

Forqué L, Valdivia A, Solano de la Asunción C, Ferrer J, Colomina J, Navarro D. 2021. Field evaluation

of a rapid antigen test (Panbio COVID-19 Ag Rapid Test Device) for COVID-19 diagnosis in primary

healthcare centres. Clin Microbiol Infect. 27(3):472.e7-472.e10. doi: 10.1016/j.cmi.2020.11.004.

Epub 2020 Nov 13. PMID: 33189872; PMCID: PMC7662075.

13. Stokes W, Berenger BM, Portnoy D, Scott B, Szelewicki J, Singh T, Venner AA, Turnbull L, Pabbaraju

K, Shokoples S, Wong AA, Gill K, Guttridge T, Proctor D, Hu J, Tipples G. 2021. Clinical performance of

the Abbott Panbio with nasopharyngeal, throat, and saliva swabs among symptomatic individuals

with COVID-19. Eur J Clin Microbiol Infect Dis. 20:1-6. doi: 10.1007/s10096-021-04202-9. Epub

ahead of print. PMID: 33742322; PMCID: PMC7979467.

14. Food and Drug Administration (FDA). 2020. Potential for false positive results with antigen tests for

rapid detection of SARS-CoV-2 - Letter to clinical laboratory staff and health care providers.

https://www.fda.gov/medical-devices/letters-health-care-providers/potential-false-positive-results-

antigen-tests-rapid-detection-sars-cov-2-letter-clinical-laboratory (accessed June 21, 2021).

15. Nikolayevskyy V, Drobniewski F. 2020. False-positive COVID-19 results: hidden problems and costs.

Lancet Respir Med. 8(12):1167-1168. doi: 10.1016/S2213-2600(20)30453-7. Epub 2020 Sep 29.

PMID: 33007240; PMCID: PMC7524437.

16. LeBlanc JJ, Heinstein C, MacDonald J, Pettipas J, Hatchette TF, Patriquin G. 2020. A combined

oropharyngeal/nares swab is a suitable alternative to nasopharyngeal swabs for the detection of

SARS-CoV-2. J Clin Virol. 128:104442. doi: 10.1016/j.jcv.2020.104442. Epub 2020 May 16. PMID:

32540034; PMCID: PMC7228872.

17. Patriquin G, Davis I, Heinstein C, MacDonald J, Hatchette TF, LeBlanc JJ. 2020. Exploring alternative

swabs for use in SARS-CoV-2 detection from the oropharynx and anterior nares. J Virol Methods.

285:113948. doi: 10.1016/j.jviromet.2020.113948. Epub 2020 Aug 9. PMID: 32783913; PMCID:

PMC7415171.

18. Goldfarb DM, Tilley P, Al-Rawahi GN, Srigley JA, Ford G, Pedersen H, Pabbi A, Hannam-Clark S,

Charles M, Dittrick M, Gadkar VJ, Pernica JM, Hoang LMN. 2021. Self-collected saline gargle samples

as an alternative to health care worker-collected nasopharyngeal swabs for COVID-19 diagnosis in

outpatients. J Clin Microbiol. 59(4):e02427-20. doi: 10.1128/JCM.02427-20. PMID: 33514627.

19. LeBlanc JJ, Pettipas J, Di Quinzio M, Hatchette TF, Patriquin G. 2021. Reliable detection of SARS-CoV-

2 with patient-collected swabs and saline gargles: A three-headed comparison on multiple molecular

platforms. Journal of Virological Methods 295:114184. doi: 10.1016/j.jviromet.2021.114184. Epub

ahead of print. PMID: 34029634; PMCID: PMC8141269.

20. Davey L, Cohen A, LeBlanc J, Halperin SA, Lee SF. 2016. The disulfide oxidoreductase SdbA is active in

Streptococcus gordonii using a single C-terminal cysteine of the CXXC motif. Mol Microbiol.

99(2):236-53. doi: 10.1111/mmi.13227. Epub 2015 Oct 30. PMID: 26395460.

21. Gao K, Oerlemans R, Groves MR. 2020. Theory and applications of differential scanning fluorimetry

in early-stage drug discovery. Biophys Rev. 12(1):85-104. doi: 10.1007/s12551-020-00619-2. Epub

2020 Jan 31. PMID: 32006251; PMCID: PMC7040159.

22. Ramu T, Prasad ME, Connors E, Mishra A, Thomassin JL, LeBlanc JJ, Rainey JK, Thomas NA. 2013. A

novel C-terminal region within the multicargo type III secretion chaperone CesT contributes to

effector secretion. J Bacteriol. 195(4):740-56. doi: 10.1128/JB.01967-12. Epub 2012 Dec 7. PMID:

23222727; PMCID: PMC3562101.

23. Gillet P, Mori M, Van den Ende J, Jacobs J. 2010. Buffer substitution in malaria rapid diagnostic tests

causes false-positive results. Malar J. 9:215. doi: 10.1186/1475-2875-9-215. PMID: 20650003;

PMCID: PMC3224932.

24. Wanji S, Amvongo-Adjia N, Njouendou AJ, Kengne-Ouafo JA, Ndongmo WP, Fombad FF, Koudou B,

Enyong PA, Bockarie M. 2016. Further evidence of the cross-reactivity of the Binax NOW Filariasis

ICT cards to non-Wuchereria bancrofti filariae: experimental studies with Loa loa and Onchocerca

ochengi. Parasit Vectors. 9:267. doi: 10.1186/s13071-016-1556-8. PMID: 27151313; PMCID:

PMC4858834.

25. Selby C. 1999. Interference in immunoassay. Ann Clin Biochem. 36(6):704-21. doi:

10.1177/000456329903600603. PMID: 10586307.

26. Nivin B, Zancocchio T. 2012. Cluster of false-positive influenza B virus rapid antigen test results in a

New York City hospital. J Clin Microbiol. 50(9):3141. doi: 10.1128/JCM.01452-12. Epub 2012 Jun 20.

PMID: 22718940; PMCID: PMC3421782.

27. Haage V, Ferreira de Oliveira-Filho E, Moreira-Soto A, Kühne A, Fischer C, Sacks JA, Corman VM,

Müller MA, Drosten C, Drexler JF. 2021. Impaired performance of SARS-CoV-2 antigen-detecting

rapid diagnostic tests at elevated and low temperatures. J Clin Virol. 138:104796. doi:

10.1016/j.jcv.2021.104796. Epub 2021 Mar 16. PMID: 33773413; PMCID: PMC7962993.

28. Lin J, Dai W, Li W, Xiao L, Luo T, Guo Y, Yang Y, Han Y, Zhu P, Wu Q, He B, Wu J, Xia X. 2021. Potential

false-positive and false-negative results for COVID-19 IgG/IgM antibody testing after heat-

inactivation. Front Med (Lausanne). 7:589080. doi: 10.3389/fmed.2020.589080. PMID: 33537325;

PMCID: PMC7849051.

29. Wehrhahn MC, Robson J, Brown S, Bursle E, Byrne S, New D, Chong S, Newcombe JP, Siversten T,

Hadlow N. 2020. Self-collection: An appropriate alternative during the SARS-CoV-2 pandemic. J Clin

406 Virol. 128:104417. doi: 10.1016/j.jcv.2020.104417. Epub 2020 May 4. PMID: 32403007; PMCID:

407 PMC7198188.

408 30. Siegler AJ, Hall E, Luisi N, Zlotorzynska M, Wilde G, Sanchez T, Bradley H, Sullivan PS. 2020.

409 Willingness to seek diagnostic testing for SARS-CoV-2 with home, drive-through, and clinic-based

410 specimen collection locations. Open Forum Infect Dis. 7(7):ofaa269. doi: 10.1093/ofid/ofaa269.

411 PMID: 32704517; PMCID: PMC7337815.

413 **Figure legends**

414 **Figure 1.** False positives SARS-CoV-2 Ag-RDT results can occur from uncontrolled pH and buffering

415 conditions. All tricine solutions were prepared in PCR-grade water known to generate false positive

416 signals when tested directly onto Panbio test devices.

417 **Figure 2**. Impact of ionic strength from NaCl on the presence of false positive SARS-CoV-2 signal

418 generated by direct processing of PCR-grade water.

419 **Figure 3**. Tolerability of the Panbio buffer to artifact generation by PCR-grade water at different

420 temperatures.

421 **Figure S1**. Conjugate pad transplantation to access and investigate properties of the proprietary Panbio

422 conjugated antibodies. Each step was followed to as depicted leading to treatment of the conjugated

423 antibodies with proteinase K (PK) or heat (T°C), and comparisons were made with untreated controls

424 (none). In some experiments (dashed arrows), the gold-conjugated antibody suspensions were pre-

425 treated with the control antibody (mouse anti-chicken IgY) was used to purify the SARS-CoV-2-specific

426 conjugated antibody (human IgG) for subsequent thermal shift assays.

**Figure S2**. Proteainase K treatment of the conjugated antibodies and removal of chicken IgY. A)

Proteinase K (PK) treatment. Using conjugate pad transplantation, gold-conjugated antibody

suspensions in Panbio buffer or water were treated for an hour with PK at 56°C, followed by heat

inactivation of PK at 70°C for 10 min. Following re-introduction into Panbio cassettes of conjugated

antibodies that were untreated (none), heat-treated (T°C), or PK-treated, water and a negative control

swab, and with buffer with either a positive or negative control swab were added to the sample well. B)

To purify the SARS-CoV-2-specific conjugated antibody (human IgG) from the conjugated antibody

suspensions, a pre-incubation with the control antibody (mouse anti-chicken IgY) excised from the

nitrocellulose membrane was performed. Untreated (none) or pre-treatment (-IgY) are depicted for

reassembled Panbio cassettes inoculated with negative or positive control swabs processed in buffer or

water.

**Figure S3**. Representative thermal shift profiles for Panbio SARS-CoV-2-specific conjugated antibody at

different pH values in 100 mM tricine. Melt temperatures (Tm) are indicated for each curve.

# Panbio buffer:water

| | 1:1 | 1:2 | 1:4 | 1:8 | 1:10 | 1:20 | 1:40 | 1:80 | 1:100 | 1:200 | 1:400 | 1:800 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (°C) | | | | | | | | | | | | | |
| 37 | NEG | NEG | NEG | NEG | NEG | POS | POS | POS | POS | POS | POS | POS | ← Control / ← Target |
| 25 | NEG | NEG | NEG | NEG | NEG | POS | POS | POS | POS | POS | POS | POS | ← Control / ← Target |
| 4 | NEG | NEG | NEG | NEG | NEG | POS | POS | POS | POS | POS | POS | POS | ← Control / ← Target |

Temperature

**Table 1.** Samples tested by SARS-CoV-2 Ag-RDTs with and without manufacturer buffer.

| Category | Brand | Description | Avg. pH (± SD) | Panbio result | | Veritor result | | RT-PCR result |
|---|---|---|---|---|---|---|---|---|
| | | | | Sample, direct | Swab of sample in buffer | Sample, direct | Swab of sample in buffer | |
| Water samples (n=24) | Sigma Life Sciences | Double processed, tissue culture water, sterile filtered | 4.00 (± 0.01) | POS | NEG | NEG | NEG | NEG |
| | Montellier | Carbonated spring water | 4.68 (± 0.00) | POS | NEG | NEG | NEG | NEG |
| | Invitrogen | UltraPure distilled water, Dnase- and Rnase-free | 4.80 (± 0.01) | POS | NEG | NEG | NEG | NEG |
| | Aquafina | Demineralized water, reverse osmosis | 5.05 (± 0.01) | POS | NEG | NEG | NEG | NEG |
| | S. Pellegrino | Carbonated natural mineral water | 5.09 (± 0.01) | POS | NEG | NEG | NEG | NEG |
| | Canadian Springs | Distilled water, osonized | 5.31 (± 0.01) | POS | NEG | NEG | NEG | NEG |
| | Dasani | Remineralized water, reverse osmosis treated | 5.68 (± 0.01) | POS | NEG | NEG | NEG | NEG |
| | Big8 | Distilled water, ozonated | 6.25 (± 0.01) | POS | NEG | NEG | NEG | NEG |
| | Big8 | Spring water, ozonated | 6.26 (± 0.01) | POS | NEG | NEG | NEG | NEG |
| | Glaceau Smart | Vapour distilled water with added electrolytes | 6.71 (± 0.02) | POS | NEG | NEG | NEG | NEG |
| | N/A | Municipal water (Halifax, Nova Scotia, May12, 2021) | 6.75 (± 0.02) | POS | NEG | NEG | NEG | NEG |
| | Fiji | Natural spring water, tropical rain filtered through volcanic rock | 7.25 (± 0.02) | POS | NEG | NEG | NEG | NEG |
| | Simple Drop | Natural spring water | 7.26 (± 0.02) | POS | NEG | NEG | NEG | NEG |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | Pathwater | Purified water, reverse osmosis treated, ozonated, and electrolytes added, pH-balanced, pH 7.5+ | 7.27 (± 0.01) | POS | NEG | NEG | NEG | NEG |
| | Art Life WTR | Purified water, mineralized and electrolytes added, pH-balanced | 7.28 (± 0.01) | POS | NEG | NEG | NEG | NEG |
| | Evian | Spring water, natural electrolytes, pH 7.2 | 7.39 (± 0.02) | POS | NEG | NEG | NEG | NEG |
| | N/A | Rain water (Halifax, Nova Scotia, May 12, 2021) | 7.47 (± 0.01) | POS | NEG | NEG | NEG | NEG |
| | Icelandic Glacial | Natural spring water | 7.58 (± 0.02) | POS | NEG | NEG | NEG | NEG |
| | Nestle Pure Life | Natural spring water, ozonated | 7.75 (± 0.02) | POS | NEG | NEG | NEG | NEG |
| | Earth Group | Spring water | 7.80 (± 0.03) | POS | NEG | NEG | NEG | NEG |
| | Eska | Natural spring water, pH 7.4 | 7.81 (± 0.00) | POS | NEG | NEG | NEG | NEG |
| | #Smart Moodwater | Naturally alkaline spring water, pH 8+ | 7.91 (± 0.01) | POS | NEG | NEG | NEG | NEG |
| | Flow | Naturally alkaline spring water, pH 8.1 | 8.02 (± 0.00) | POS | NEG | NEG | NEG | NEG |
| | Glaceau Smart | Mineralized treated water, alkaline pH 9+ | 9.33 (± 0.00) | POS | NEG | NEG | NEG | NEG |
| Laboratory buffers and media (n=14) | Teligent | 0.9% Saline | 5.62 (± 0.02) | POS (weak) | NEG | NEG | NEG | NEG |
| | Boston BioProducts | 0.5M Pipes buffer, pH 6.8 | 6.66 (± 0.01) | POS* | NEG | NEG | NEG | NEG |
| | FisherScientific | 10 mM Tris-HCl; 1 mM EDTA (TE) buffer, molecular-grade pH 7.4 | 7.14 (± 0.01) | POS | NEG | NEG | NEG | NEG |
| | Sigma Life Sciences | Dulbecco's Phosphate Buffered Saline (PBS) | 7.18 (± 0.01) | POS* | NEG | NEG | NEG | NEG |
| | LiofilChem | Viral Transport Media (VTM) | 7.24 (± 0.01) | POS* | NEG | NEG | NEG | NEG |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | Redoxica | Viral Transport Media (VTM) with fetal bovine serum (FBS) | 7.33 (± 0.01) | POS* | NEG | NEG | NEG | NEG |
| | Becton Dickinson | Veritor sample buffer | 7.33 (± 0.00) | NEG | NEG | NEG | NEG | NEG |
| | Copan Diagnostics | Universal Transport Medium (UTM) | 7.37 (± 0.01) | NEG | NEG | NEG | NEG | NEG |
| | Yokon | Universal Transport Medium (UTM) | 7.44 (± 0.01) | NEG | NEG | NEG | NEG | NEG |
| | Gibco | RPMI medium 1640, with HEPES | 7.48 (± 0.01) | NEG | NEG | NEG | NEG | NEG |
| | Genesis | KaiBiLi Extended ViralTrans, includes HEPES | 7.50 (± 0.01) | NEG | NEG | NEG | NEG | NEG |
| | Gibco | Minimal Essential Media (MEM) | 7.83 (± 0.01) | NEG | NEG | NEG | NEG | NEG |
| | Gibco | 1x Phosphate Buffered Saline (PBS), pH 7.4 | 8.20 (± 0.01) | NEG | NEG | NEG | NEG | NEG |
| | Abbott | Panbio sample buffer | 8.78 (± 0.01) | NEG | NEG | NEG | NEG | NEG |
| Clinical specimens (n=120) | N/A | NP swabs in UTM (n=30) | N/A | POS* (28/30) | NEG | NEG | NEG | NEG |
| | N/A | OP/N swabs in PBS (n=30) | N/A | POS* (26/30) | NEG | NEG | NEG | NEG |
| | N/A | BALs (n=30) | N/A | POS* (27/30) | NEG | NEG | NEG | NEG |
| | N/A | Saline gargles (n=30) | N/A | POS* (27/30) | NEG | NEG | NEG | NEG |

*Only weak positive reactions were observed.